Advertisement

Organisation › Details
Cevec (Group)
CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP®GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP®GT suspension cell-derived viral packaging cell lines, including a stable, helper virus-free AAV production platform, which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP®GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentiviral, adenoviral, and adeno-associated viral (AAV) vectors can be produced at industrial scale. CAP®Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns. *
![]() |
Start | 2001-01-01 established |
Today | Cevec Pharmaceuticals GmbH | |
![]() |
Industry | cell line/system (recombinant protein production) |
Industry 2 | CAP® technology (Cevec) | |
![]() |
Person | Faust, Nicole (Cevec 201904 CEO + CSO joined Cevec 201105 before amaxa + Artemis Pharmaceuticals) |
Person 2 | Kettling, Ulrich (Cevec 202004 CBO) | |
![]() |
Region | Köln (Cologne) |
Country | Germany | |
Street | 62 Gottfried-Hagen-Str. | |
City | 51105 Köln | |
Tel | +49-221-460208-00 | |
Address record changed: 2020-12-11 | ||
Basic data | Employees | B: 11 to 50 (2010-01-01) |
* Document for �About Section�: Cevec Pharmaceuticals GmbH. (4/16/19). "Press Release: Cevec Closes Major Financing Round to Further Expand and Commercialize Its Viral Vector Manufacturing Platform". Cologne. | ||
Record changed: 2020-12-11 |
Advertisement

More documents for Cevec (Group)
- [1] Cevec Pharmaceuticals GmbH. (1/8/21). "Press Release: Cevec Announces New License Agreement for Its AAV Manufacturing Technology Elevecta in Gene Therapy". Cologne....
- [2] Merck KGaA. (12/11/20). "Press Release: Bavencio (avelumab) Receives Positive CHMP Opinion for First-line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma". Darmstadt....
- [3] Cevec Pharmaceuticals GmbH. (11/10/20). "Press Release: Cevec Signs Agreement with Roche for the Use of Cevec’s Elevecta Technology in Gene Therapy". Cologne....
- [4] Cevec Pharmaceuticals GmbH. (10/19/20). "Press Release: Cevec and Rznomics Sign License Agreement for the Use of CAP® Technology in Manufacturing of Adenoviral Vectors"....
- [5] Cevec Pharmaceuticals GmbH. (4/16/20). "Press Release: Cevec Signs License Agreement for the Development and Commercialization of Exosomes for Therapeutic Use". Cologne....
- [6] Cevec Pharmaceuticals GmbH. (4/16/19). "Press Release: Cevec Closes Major Financing Round to Further Expand and Commercialize Its Viral Vector Manufacturing Platform". Cologne....
- [7] Cevec Pharmaceuticals GmbH. (5/8/18). "Press Release: Cevec and CSL Limited Sign Exclusive License Agreement for Production of Recombinant C1 Esterase Inhibitor Using Cevec’s Proprietary CAPGo Technology". Cologne & Melbourne....
- [8] Cevec Pharmaceuticals GmbH. (3/16/17). "Press Release: Cevec, Medac and Provecs Medical Enter into Far-reaching Adenoviral Vector Collaboration in Oncology". Cologne, Wedel & Hamburg....
- [9] Cevec Pharmaceuticals GmbH. (2/9/17). "Press Release: Cevec Licenses CAP Technologies for the Development and Commercialization of Vaccines against Zika Virus Infections". Cologne....
- [10] Cevec Pharmaceuticals GmbH. (1/20/16). "Press Release: Cevec and Beckman Research Institute of City of Hope Enter into a Cooperation and License Agreement on Cevec’s Proprietary CAP®GT Technology". Cologne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
» top